Literature DB >> 2649424

Adenocarcinoma of the uterine cervix: prognostic factors and patterns of recurrence.

H M Goodman1, C A Buttlar, J M Niloff, W R Welch, A Marck, E J Feuer, E A Lahman, E L Jenison, R C Knapp.   

Abstract

Survival data, prognostic factors, and patterns of recurrence were analyzed for 70 women with adenocarcinoma of the uterine cervix treated between 1968 and 1982. The 5-year survival rates for stages I, II, and III-IV were 82, 90, and 38%, respectively. Control of pelvic tumor was achieved in 82, 80, and 12.5% of cases of stage I, II, and III-IV disease, respectively. When radiation therapy techniques alone were employed, pelvic control was achieved in 100% of stage I and 75% of stage II cases. Tumor grade was an important prognostic factor in stage I disease, with 92% of patients with grade 1 and 2 lesions surviving 5 years, in contrast to 68% of patients with grade 3 lesions (P less than 0.05, log rank test).

Entities:  

Mesh:

Year:  1989        PMID: 2649424     DOI: 10.1016/0090-8258(89)90560-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Clinical determinants of survival from stage Ib cervical cancer in an inner-city hospital.

Authors:  W W Thoms; E R Unger; R Carisio; R Nisenbaum; C O Spann; I R Horowitz; W C Reeves
Journal:  J Natl Med Assoc       Date:  1998-05       Impact factor: 1.798

2.  Comparison of outcomes between squamous cell carcinoma and adenocarcinoma in patients with surgically treated stage I-II cervical cancer.

Authors:  Makoto Yamauchi; Takeshi Fukuda; Takuma Wada; Masaru Kawanishi; Kenji Imai; Yasunori Hashiguchi; Tomoyuki Ichimura; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Mol Clin Oncol       Date:  2014-05-15

3.  Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy.

Authors:  Tatsuya Kato; Hidemichi Watari; Mahito Takeda; Masayoshi Hosaka; Takashi Mitamura; Noriko Kobayashi; Satoko Sudo; Masanori Kaneuchi; Masataka Kudo; Noriaki Sakuragi
Journal:  J Gynecol Oncol       Date:  2013-07-04       Impact factor: 4.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.